McElree, I.M.; Packiam, V.T.; Steinberg, R.L.; Hougen, H.Y.; Mott, S.L.; Abou Chakra, M.; Zakharia, Y.; O’Donnell, M.A.
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers 2024, 16, 2561.
https://doi.org/10.3390/cancers16142561
AMA Style
McElree IM, Packiam VT, Steinberg RL, Hougen HY, Mott SL, Abou Chakra M, Zakharia Y, O’Donnell MA.
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers. 2024; 16(14):2561.
https://doi.org/10.3390/cancers16142561
Chicago/Turabian Style
McElree, Ian M., Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Mohamad Abou Chakra, Yousef Zakharia, and Michael A. O’Donnell.
2024. "Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor" Cancers 16, no. 14: 2561.
https://doi.org/10.3390/cancers16142561
APA Style
McElree, I. M., Packiam, V. T., Steinberg, R. L., Hougen, H. Y., Mott, S. L., Abou Chakra, M., Zakharia, Y., & O’Donnell, M. A.
(2024). Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers, 16(14), 2561.
https://doi.org/10.3390/cancers16142561
